UK-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Bohannan, a Walmart asset protection investigator, is running for Topeka City Council District 1. Bohannan's campaign priorities include addressing homelessness, infrastructure and education.

Media Capital Technologies (MCT) and The Horror Section will fully finance and produce “Ice Cream Man,” Eli Roth’s new horror film. Roth, a master of the genre whose work includes the ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing its first drug asset from the deal. Lilly will pay up to $415 million in ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with Purdue University over the next eight years. The boosted pact with the ...

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs ...

Amyotrophic lateral sclerosis has been a tough area for drug research, but Eli Lilly has been spreading its bets in this neurodegenerative disease by striking deals with other companies.

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...

The company's new oral GLP-1 drug, which avoids the use of injections, has huge potential. Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook ...

We may receive a commission on purchases made from links. There's a lot to love about the Milwaukee Packout system, especially since you can easily visualize its entire look and set up on the ...